Company Overview and News


Add AGTC
to your dashboard

Headline News

Editors' Picks Daily: Is Downsizing A Fad?

2017-11-13 seekingalpha
Articles get tagged with an Editors’ Pick award when they appeal to a broad audience and demonstrate convincing analysis and a clear actionable takeaway. (46-2)

Applied Genetic Technologies Corp.: A Forgotten Net-Net With Clear Upside Catalysts

2017-11-10 seekingalpha
AGTC has been continuing to advance its orphan drug candidates through its proprietary gene platform with XLRS the furthest along. (126-0)

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q1 2018 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good day and welcome to the AGTC Financial Results Conference Call for the First Quarter of Fiscal Year 2018. Today's call is being recorded. Before we get started, I'd like to remind everyone that during this conference call AGTC may make forward-looking statements, including statements about the Company’s financial results, its future business strategies and operations, and product development and regulatory progress. (67-1)

Nightstar Therapeutics - Novel Gene Therapy Company And Recent IPO

2017-10-16 seekingalpha
The 2018 data release in X-linked retinitis pigmentosa indication is the next catalyst for the stock price. (81-0)

Earnings Review and Free Research Report: Applied Genetic Announced Q4 and Full Year FY17 Results

2017-10-02 accesswire
LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Applied Genetic Technologies Corp. (NASDAQ: AGTC) ("Applied Genetic"), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AGTC, following the Company's disclosure of its financial results on September 13, 2017, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and full year 2017 (FY17). (54-1)

Earnings Review and Free Research Report: Aviragen Reported its Q4 and Full Year FY17 Results

2017-09-25 accesswire
LONDON, UK / ACCESSWIRE / September 25, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Aviragen Therapeutics, Inc. (NASDAQ: AVIR), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AVIR, following the Company's reporting of its financial results on August 31, 2017, for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17). The Atlanta, Georgia-based Company's net loss narrowed during the reported quarter. (88-0)

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q4 2017 Results - Earnings Call Transcript

2017-09-13 seekingalpha
Good morning and welcome to the AGTC Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call. Today's call is being recorded. Before we get started, I'd like to remind everyone that during this conference call AGTC may make forward-looking statements, including statements about the Company’s financial results, its future business strategies and operations, and product development and regulatory progress. (2-1)

Applied Genetic Technologies Corporation (AGTC) Presents At Wedbush PacGrow Healthcare Conference - Slideshow

2017-08-17 seekingalpha
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with this event. (0-1)

IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia Nasdaq:AGTC

2017-07-21 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of IND-enabling preclinical data demonstrating the safety and efficacy of AGTC-402 in the treatment of achromatopsia (ACHM) due to mutations in the CNGA3 gene.

AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness (NASDAQ:AGTC)

2017-07-21 ir.agtc
NEW YORK, GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

Safety profile of Genetic Tech's AAV-based gene therapy OK in early-stage study of inherited vision loss disorder - Applied Genetic Technologies Corporation (NASDAQ:AGTC) | Seeking Alpha

2017-07-21 seekingalpha
Top-line safety data from a Phase 1/2 clinical trial assessing Applied Genetic Technologies' (NASDAQ:AGTC) adeno-associated virus (AAV)-based gene therapy for the treatment of X-linked retinoschisis identified no serious treatment-related serious adverse events. The most common adverse event was mild-to-moderate ocular inflammation which was resolved or controlled without further intervention or after treatment with topical or oral corticosteroids.

Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy | Xconomy

2017-07-21 xconomy
Biogen’s revitalized interest in gene therapy continues with a deal the Cambridge, MA-based biotech giant announced this morning. (0-1)

Biotech Forum Daily Digest - Spotlight On Applied Genetics Technology

2017-06-14 seekingalpha
New leadership at the FDA is starting to target the opioid epidemic that has blossomed over the past decade which has ramifications for the pain management industry.

Applied Genetic Technologies (AGTC) Presents At 29th Annual ROTH Conference

2017-03-15 seekingalpha
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with this event.

CUSIP: 03820J100